Cargando…

Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients

SIMPLE SUMMARY: In this research study, the authors investigated the impact of specific genetic mutations on the survival of lung cancer patients with brain metastases who underwent surgical resection. These mutations, known as anaplastic lymphoma kinase (ALK)-rearranged and epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannam, Sneha Sai, Bray, David P., Nwagwu, Chibueze D., Zhong, Jim, Shu, Hui-Kuo, Eaton, Bree, Sudmeier, Lisa, Goyal, Subir, Deibert, Christopher, Nduom, Edjah K., Olson, Jeffrey, Hoang, Kimberly B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572022/ https://www.ncbi.nlm.nih.gov/pubmed/37835467 http://dx.doi.org/10.3390/cancers15194773

Ejemplares similares

LOCL-05 CEREBRAL METASTATIC LUNG CARCINOMA: EFFECT OF ALK- AND EGFR-MUTATION STATUS AND SURGICAL MANAGEMENT UPON CLINICAL OUTCOME
por: Mannam, Sneha Sai, et al.
Publicado: (2022)

Perfusion-Weighted Imaging: The Use of a Novel Perfusion Scoring Criteria to Improve the Assessment of Brain Tumor Recurrence versus Treatment Effects
por: Mannam, Sneha Sai, et al.
Publicado: (2023)

Distinct phenotypic states and spatial distribution of CD8(+) T cell clonotypes in human brain metastases
por: Sudmeier, Lisa J., et al.
Publicado: (2022)

Artificial neural networks predict the need for permanent cerebrospinal fluid diversion following posterior fossa tumor resection
por: Bray, David P, et al.
Publicado: (2022)

Why would a black man volunteer for a government-funded science experiment?
por: Nduom, Edjah K.
Publicado: (2021)

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

Current Options and Future Directions in Immune Therapy for Glioblastoma
por: Lynes, John, et al.
Publicado: (2018)

Neuroendoscopic Resection of Intraventricular Tumors and Cysts through a Working Channel with a Variable Aspiration Tissue Resector: A Feasibility and Safety Study
por: Nduom, Edjah Kweku-Ebura, et al.
Publicado: (2013)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC
por: Sit, Daegan, et al.
Publicado: (2022)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Surgical Outcomes of Novel Collagen Tile Cesium Brachytherapy for Recurrent Intracranial Tumors at a Tertiary Referral Center
por: Warren, Kwanza T, et al.
Publicado: (2021)

Immune niches in brain metastases contain TCF1+ stem-like T cells, are associated with disease control and are modulated by preoperative SRS
por: Jansen, Caroline S., et al.
Publicado: (2023)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Brain Tumor Discussions on Twitter (#BTSM): Social Network Analysis
por: Feliciano, Josemari T, et al.
Publicado: (2020)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging
por: Nwagwu, Chibueze D., et al.
Publicado: (2020)

Clinically Explored Virus-Based Therapies for the Treatment of Recurrent High-Grade Glioma in Adults
por: Immidisetti, Amanda V., et al.
Publicado: (2021)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
por: Rothschild, Sacha I.
Publicado: (2015)

Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey
por: Sag, Sebnem Ozemri, et al.
Publicado: (2016)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
por: Lee, Boram, et al.
Publicado: (2016)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Immune microenvironment remodeling after radiation of a progressing brain metastasis
por: Hudson, William H., et al.
Publicado: (2023)

Surgery for acromegaly: Indications and goals
por: Bray, David P., et al.
Publicado: (2022)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

miR-138 exerts anti-glioma efficacy by targeting immune checkpoints
por: Wei, Jun, et al.
Publicado: (2013)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
por: Spaans, Johanna N., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i5thi24l1d09olam2i9g8nk7p3